Nuveen Asset Management LLC Purchases 100,206 Shares of Evolent Health, Inc. (NYSE:EVH)

Posted by Defense World Staff on Feb 27th, 2023

Nuveen Asset Management LLC increased its position in shares of Evolent Health, Inc. (NYSE:EVH – Get Rating) by 9.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,136,785 shares of the technology company’s stock after buying an additional 100,206 shares during the period. Nuveen Asset Management LLC owned 1.12% of Evolent Health worth $40,845,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Altshuler Shaham Ltd acquired a new position in shares of Evolent Health in the 3rd quarter valued at about $25,000. Captrust Financial Advisors lifted its position in shares of Evolent Health by 254.4% during the 2nd quarter. Captrust Financial Advisors now owns 1,758 shares of the technology company’s stock valued at $54,000 after acquiring an additional 1,262 shares during the period. Ameliora Wealth Management Ltd. acquired a new stake in Evolent Health in the third quarter worth $61,000. Quantbot Technologies LP bought a new stake in Evolent Health in the third quarter valued at $78,000. Finally, Spire Wealth Management acquired a new position in shares of Evolent Health during the third quarter valued at about $81,000. Institutional investors and hedge funds own 93.33% of the company’s stock.

Evolent Health Price Performance

NYSE EVH opened at $34.91 on Monday. The company has a market cap of $3.53 billion, a PE ratio of -174.54 and a beta of 1.56. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The firm’s 50-day simple moving average is $30.35 and its two-hundred day simple moving average is $31.42. Evolent Health, Inc. has a 52 week low of $21.83 and a 52 week high of $39.78.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on EVH. Canaccord Genuity Group dropped their price target on Evolent Health from $48.00 to $44.00 in a research note on Thursday, November 3rd. Cowen lifted their price target on shares of Evolent Health from $57.00 to $59.00 and gave the company an “outperform” rating in a research report on Monday, January 30th. BTIG Research upped their price objective on shares of Evolent Health from $40.00 to $45.00 in a report on Thursday. Truist Financial reduced their price objective on shares of Evolent Health to $32.00 in a report on Thursday, November 17th. Finally, StockNews.com lowered shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Friday, November 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $47.70.

Insider Activity at Evolent Health

In other news, Director Frank J. Williams sold 110,000 shares of the firm’s stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $27.15, for a total value of $2,986,500.00. Following the completion of the transaction, the director now directly owns 626,479 shares of the company’s stock, valued at $17,008,904.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.20% of the stock is owned by company insiders.

Evolent Health Company Profile

(Get Rating)

Evolent Health, Inc engages in the provision of health care delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration.